… New evidence suggests that the combination of BRAF and MEK inhibitors improves tumor …
and MEK (trametinib) inhibitors as well as the available data on BRAF inhibitor + MEK inhibitor …

… the subsequent clinical trials combining inhibitors of both MEK and mutant BRAF … inhibitor
monotherapy. In this review, we discuss existing clinical trial data on BRAF and MEK inhibitors …

… MEK inhibitors … melanoma due to their ability to inhibit melanoma cell lines with BRAF and
NRAS mutations. In BRAF-mutated melanoma, phase II and III trials have shown that the MEK …

… We show that ERK inhibition is more potent than MEK inhibition at suppressing MAPK … of
multiple BRAF inhibitor resistant melanoma cell models. Nevertheless, melanoma cells often …

… and clinical data regarding MEK inhibitors and their role in the treatment of advanced
melanoma. … A partial listing of key clinical trials of MEK inhibitors in melanoma is listed in Table 1. …

… therapy in BRAF-mutated melanomas, its future utility has … melanoma respond to MEK
inhibitor-based therapy, Citation38 what may extend the indication for MEK inhibitors in melanoma …

… combination therapy of BRAF and MEK inhibition achieved better curative effect and …
inhibition plus MEK inhibition combination therapy and BRAF inhibition monotherapy in melanoma …

… BRAF inhibition and explore the safety of combination therapy with BRAF and MEK inhibition…
inhibitor dabrafenib and the MEK inhibitor trametinib in patients with metastatic BRAF V600 …

… metastatic melanoma, and we explore the three major effectors of BRAF/MEK inhibitor
resistance … to further improve outcomes for patients with BRAF-mutated metastatic melanoma. …

… when compared with MEK inhibitors. Indeed, different allosteric MEK inhibitors can affect
feedback to MEK inhibition (45–47) and similar differences may also occur with ERK …